JP2015502400A - リポソームの亜塩素酸塩または塩素酸塩組成物 - Google Patents

リポソームの亜塩素酸塩または塩素酸塩組成物 Download PDF

Info

Publication number
JP2015502400A
JP2015502400A JP2014548324A JP2014548324A JP2015502400A JP 2015502400 A JP2015502400 A JP 2015502400A JP 2014548324 A JP2014548324 A JP 2014548324A JP 2014548324 A JP2014548324 A JP 2014548324A JP 2015502400 A JP2015502400 A JP 2015502400A
Authority
JP
Japan
Prior art keywords
composition
liposome
chlorite
liposomes
chlorate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014548324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502400A5 (enExample
Inventor
マーティン，レイナー
アルンホルト，ユルゲン
ロベルト ザイフェルト
ロベルト ザイフェルト
キングースミス，ドミニク
テージャス デサイ，
テージャス デサイ，
ワグナー，アンドレアス
Original Assignee
ヌーボ リサーチ ゲイエムベーハー
ヌーボ リサーチ ゲイエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌーボ リサーチ ゲイエムベーハー, ヌーボ リサーチ ゲイエムベーハー filed Critical ヌーボ リサーチ ゲイエムベーハー
Publication of JP2015502400A publication Critical patent/JP2015502400A/ja
Publication of JP2015502400A5 publication Critical patent/JP2015502400A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2014548324A 2011-12-22 2012-12-21 リポソームの亜塩素酸塩または塩素酸塩組成物 Pending JP2015502400A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579326P 2011-12-22 2011-12-22
US61/579,326 2011-12-22
PCT/IB2012/057645 WO2013093891A1 (en) 2011-12-22 2012-12-21 Liposomal chlorite or chlorate compositions

Publications (2)

Publication Number Publication Date
JP2015502400A true JP2015502400A (ja) 2015-01-22
JP2015502400A5 JP2015502400A5 (enExample) 2015-11-05

Family

ID=47630448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548324A Pending JP2015502400A (ja) 2011-12-22 2012-12-21 リポソームの亜塩素酸塩または塩素酸塩組成物

Country Status (11)

Country Link
US (1) US20130177629A1 (enExample)
EP (1) EP2793860A1 (enExample)
JP (1) JP2015502400A (enExample)
CN (1) CN104125826A (enExample)
AU (1) AU2012297589C1 (enExample)
BR (1) BR112014015333A2 (enExample)
CA (1) CA2857604A1 (enExample)
IN (1) IN2014DN05866A (enExample)
MX (1) MX2014007664A (enExample)
RU (1) RU2014130080A (enExample)
WO (1) WO2013093891A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018523711A (ja) * 2015-08-20 2018-08-23 オーエックスオー ケミ（タイランド）カンパニー、リミテッド 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006322076C1 (en) 2005-12-08 2013-11-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2014037927A1 (en) * 2012-09-10 2014-03-13 Nuvo Research Gmbh Chlorate compositions and use of chlorate for treating radiation exposure
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
EP3466432B1 (en) 2014-05-15 2020-07-08 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
TWI719105B (zh) 2016-01-04 2021-02-21 中央硏究院 基於酯化/皂化用於微脂體負載之方法
US20190142864A1 (en) * 2017-10-11 2019-05-16 California Institute Of Technology Methods and systems, for interfering with viability of bacteria and related antimicrobials and compositions
EP3752833B1 (en) * 2018-02-15 2025-08-13 Yeditepe Universitesi Exosome isolation method by two phase fluid system
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN110563829B (zh) * 2019-09-17 2021-03-26 中国人民解放军国防科技大学 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用
CN112716973A (zh) * 2019-10-28 2021-04-30 卢序 一种降低细胞还原应激的氧化剂的用途
TR202012260A2 (tr) * 2020-08-05 2020-10-21 Emin Zuemruetdal Oral kullanim i̇çi̇n potasyum hi̇droksi̇t/sodyum hi̇droksi̇t solüsyonu
CA3253808A1 (en) * 2022-05-19 2023-11-23 Neuvivo Inc BIOMARKERS OF NEURODEGENERATIVE DISEASES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522109A (ja) * 1998-10-08 2003-07-22 エル． キャラグーチアン、ハンパー 亜塩素酸塩と過酸化水素とを含有する共同作用抗菌性皮膚科・眼科製剤
KR20030072766A (ko) * 2002-03-06 2003-09-19 (주)인터커머스 구취 억제능이 우수한 구강 위생용 조성물 및 그의제조방법
JP2009521473A (ja) * 2005-12-22 2009-06-04 タイジ・バイオメデイカル・インコーポレーテツド 亜塩素酸塩製剤、およびこの調製の方法と利用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE3213389A1 (de) 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
US4551288A (en) 1982-08-16 1985-11-05 Sandoz, Inc. Processes for the preparation of liposome drug delivery systems
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4574084A (en) 1983-02-25 1986-03-04 Peter Berger Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
DE3515745A1 (de) 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
DE3625867C2 (de) 1986-07-31 1995-10-19 Elstner Erich F Prof Dr Verwendung von Tetrachlordecaoxid in der Ophthalmologie
US4781871A (en) 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4752425A (en) 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
WO1988007850A1 (en) 1987-04-16 1988-10-20 The Liposome Company, Inc. Liposome continuous size reduction method and apparatus
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US4851222A (en) 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5190822A (en) 1990-04-20 1993-03-02 Fuji Photo Film Co., Ltd. Surface-modifiable liposome and process for producing surface-modified liposome
US5206027A (en) 1990-09-13 1993-04-27 Fuji Photo Film Co., Ltd. Amphipathic compound and liposome comprising the same
WO1992007959A1 (en) 1990-11-05 1992-05-14 Biowhittaker Inc. Homogeneous membrane lytic immunoassay method utilizing contact sensitive liposome formulations
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
JPH06206825A (ja) 1992-12-11 1994-07-26 Nippon Rooshiyon Kk 白癬菌、湿疹等による皮膚病の治療剤及び 皮膚殺菌活性化剤
EP0616801B1 (de) 1993-03-24 1998-05-27 Novartis AG Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich
CA2179014C (en) 1993-12-17 2003-07-29 Spinal Cord Society Method for inducing dna synthesis in neurons
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6110666A (en) 1994-06-09 2000-08-29 Medical Research Council Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure
US5786214A (en) 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
ES2217582T3 (es) 1997-10-06 2004-11-01 Oxo Chemie Ag Uso de una disolucion de clorito quimicamente estabilizada para inhibir una respuesta inmunitaria especifica de un antigeno.
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
AU759164C (en) 1997-11-19 2007-03-29 Georgetown University Targeted liposome gene delivery
WO1999041403A1 (en) 1998-02-12 1999-08-19 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
US6132702A (en) 1998-02-27 2000-10-17 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6077502A (en) 1998-02-27 2000-06-20 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6251372B1 (en) 1998-02-27 2001-06-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6350438B1 (en) 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
WO2000019981A1 (en) 1998-10-08 2000-04-13 Karagoezian Hampar L Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
IL148189A0 (en) 1999-08-18 2002-09-12 Oxo Chemie Ag Chemically-stabilized chlorite solutions for treating cancer and other diseases
WO2001017030A1 (en) 1999-08-27 2001-03-08 Macronix America, Inc. Non-volatile memory structure for twin-bit storage and methods of making same
US20070104798A1 (en) * 1999-10-04 2007-05-10 S.K. Pharmaceuticals, Inc. Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide
JP2003514843A (ja) 1999-11-24 2003-04-22 ザ リポソーム カンパニー、インコーポレーテッド モジュラー標的化リポソーム送達システム
CA2394717C (en) 1999-12-30 2011-05-17 Judith K. Gwathmey Iron chelator delivery system
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7101985B2 (en) 2001-11-20 2006-09-05 Baylor College Of Medicine Methods and compositions in checkpoint signaling
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8765808B2 (en) * 2005-03-23 2014-07-01 Chs Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
AU2006272343B2 (en) 2005-07-21 2012-09-13 Nuvo Research Ag Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
EP1971426A1 (de) 2006-01-11 2008-09-24 P & W Invest Vermögensverwaltungsgesellschaft mbH Hüllenmembran zur abgabe eines eingeschlossenen wirkstoffs, ein verfahren zur herstellung sowie deren verwendung
US8252343B2 (en) 2007-06-01 2012-08-28 Nuvo Research Ag Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
US20110052655A1 (en) 2007-08-08 2011-03-03 Wilson Kurt Whitekettle Methods and vesicles for controlling protozoa
EP2449114B9 (en) * 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US20110177147A1 (en) 2010-01-21 2011-07-21 General Electric Company Stable biocidal delivery systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522109A (ja) * 1998-10-08 2003-07-22 エル． キャラグーチアン、ハンパー 亜塩素酸塩と過酸化水素とを含有する共同作用抗菌性皮膚科・眼科製剤
KR20030072766A (ko) * 2002-03-06 2003-09-19 (주)인터커머스 구취 억제능이 우수한 구강 위생용 조성물 및 그의제조방법
JP2009521473A (ja) * 2005-12-22 2009-06-04 タイジ・バイオメデイカル・インコーポレーテツド 亜塩素酸塩製剤、およびこの調製の方法と利用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018523711A (ja) * 2015-08-20 2018-08-23 オーエックスオー ケミ（タイランド）カンパニー、リミテッド 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用
JP2021130664A (ja) * 2015-08-20 2021-09-09 フリードリッヒ − ヴィルヘルム キューネ 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用
US11813234B2 (en) 2015-08-20 2023-11-14 Oxo Translational Science Gmbh Use of chlorite to treat red blood cell diseases and indications mediated thereby

Also Published As

Publication number Publication date
EP2793860A1 (en) 2014-10-29
US20130177629A1 (en) 2013-07-11
CN104125826A (zh) 2014-10-29
CA2857604A1 (en) 2013-06-27
AU2012297589A1 (en) 2013-07-11
BR112014015333A8 (pt) 2017-06-13
AU2012297589C1 (en) 2015-04-16
IN2014DN05866A (enExample) 2015-05-22
WO2013093891A1 (en) 2013-06-27
BR112014015333A2 (pt) 2017-06-13
MX2014007664A (es) 2015-05-11
AU2012297589B2 (en) 2014-10-30
RU2014130080A (ru) 2016-02-10

Similar Documents

Publication Publication Date Title
JP2015502400A (ja) リポソームの亜塩素酸塩または塩素酸塩組成物
JP7555630B2 (ja) カロテノイド組成物およびその使用
JP5767580B2 (ja) 薬剤送達のためのリポソームおよびその調製方法
JP4555569B2 (ja) 増強された血中安定性を有する脂質キャリア組成物
JP5778160B2 (ja) ｓＰＬＡ２加水分解性リポソームを含む医薬組成物
DE60122304T2 (de) Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
TW201725039A (zh) 穩定之喜樹鹼醫藥組合物
JP2012529501A (ja) ホスファチジルエタノールアミンを含む音響感受性薬物送達粒子
US20110020428A1 (en) Gel-stabilized liposome compositions, methods for their preparation and uses thereof
CN1938048B (zh) 脂质体制剂
JP2024505154A (ja) ウチデロンリポソーム組成物、及びその製造方法並びに使用
KR20240037280A (ko) 리포솜 제형의 제조 방법
EP2398463A1 (en) A method for amphiphilic drug loading in liposomes by ion gradient
JP2025026896A (ja) リポソームドキソルビシン製剤、リポソームドキソルビシン製剤の製造方法、および薬剤としてのリポソームドキソルビシン製剤の使用
JP2019527692A (ja) 弱酸性の活性作用物質を含有しているリポソーム組成物
EP2252304B1 (en) Platinum aggregates and process for producing the same
EP4209229A1 (en) Liposome preparation containing antibacterial drug
JP2015010069A (ja) ポリエンマクロライド系抗生物質の液状プレミックス製剤、その製造方法
HK1150979A (en) Platinum aggregates and process for producing the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170523